CTLA4 and glioblastoma: With the continuous exploration of alternative treatment options, people are raising their interest in glioblastoma(GBM) immunotherapy, especially checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)2.